{'52WeekChange': 0.65575075,
 'SandP52WeekChange': None,
 'address1': 'Clarendon House',
 'address2': '2 Church Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 20.03,
 'askSize': 900,
 'averageDailyVolume10Day': 653037,
 'averageVolume': 337438,
 'averageVolume10days': 653037,
 'beta': 0,
 'beta3Year': None,
 'bid': 20,
 'bidSize': 1200,
 'bookValue': 3.703,
 'category': None,
 'circulatingSupply': None,
 'city': 'Hamilton',
 'companyOfficers': [],
 'country': 'Bermuda',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 20.585,
 'dayLow': 19.56,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -7.372,
 'enterpriseToRevenue': None,
 'enterpriseValue': 954803520,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 23.191143,
 'fiftyTwoWeekHigh': 28.67,
 'fiftyTwoWeekLow': 5.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 21832978,
 'forwardEps': -2.69,
 'forwardPE': -7.446097,
 'fromCurrency': None,
 'fullTimeEmployees': 135,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.06959,
 'heldPercentInstitutions': 0.69973,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/kiniksa.com',
 'longBusinessSummary': 'Kiniksa Pharmaceuticals, Ltd., a clinical-stage '
                        'biopharmaceutical company, focuses on discovering, '
                        'acquiring, developing, and commercializing '
                        'therapeutic medicines for patients suffering from '
                        'debilitating diseases with significant unmet medical '
                        'need worldwide. Its clinical-stage product candidates '
                        'include Rilonacept, which is in Phase III clinical '
                        'trials for the treatment of recurrent pericarditis, '
                        'an inflammatory cardiovascular disease; Mavrilimumab, '
                        'a monoclonal antibody that is in Phase II clinical '
                        'trials for the treatment of giant cell arteritis; and '
                        'KPL-716, a monoclonal antibody, which is in Phase 2a '
                        'clinical trial for the treatment of prurigo '
                        'nodularis, a chronic inflammatory skin condition; and '
                        'in Phase 1a clinical trial for the treatment of '
                        "atopic dermatitis. The company's preclinical product "
                        'candidates comprise KPL-404, a monoclonal antibody '
                        'inhibitor of the CD40/CD40L interaction, a central '
                        'control node of T-cell-dependent, and B-cell-mediated '
                        'humoral adaptive immunity. The company has a clinical '
                        'collaboration with Kite Pharma, Inc. to evaluate '
                        'investigational combination of Yescarta and '
                        'Mavrilimumab in patients with relapsed or refractory '
                        'Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. '
                        'was founded in 2015 and is based in Hamilton, '
                        'Bermuda.',
 'longName': 'Kiniksa Pharmaceuticals, Ltd.',
 'market': 'us_market',
 'marketCap': 1211546624,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_558211765',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -122465000,
 'nextFiscalYearEnd': 1640908800,
 'open': 20.38,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.1,
 'phone': '808 189 6257',
 'previousClose': 20.73,
 'priceHint': 2,
 'priceToBook': 5.4091277,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 20.585,
 'regularMarketDayLow': 19.56,
 'regularMarketOpen': 20.38,
 'regularMarketPreviousClose': 20.73,
 'regularMarketPrice': 20.38,
 'regularMarketVolume': 557635,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 25370000,
 'sharesPercentSharesOut': 0.0476,
 'sharesShort': 2787410,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2501734,
 'shortName': 'Kiniksa Pharmaceuticals, Ltd.',
 'shortPercentOfFloat': 0.1295,
 'shortRatio': 9.02,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'KNSA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.229,
 'twoHundredDayAverage': 18.934174,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '7ea20e71-749b-31b8-994b-79f75933ead7',
 'volume': 557635,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.kiniksa.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'HM 11'}